Risk Factors Update Summary
- The Medicaid Prescription Drug Rebate cap was eliminated, impacting revenue erosion and business strategies.
- The IRA will reduce prices and reimbursements for certain products, affecting revenue and IP protection.
- The IRA requires drug manufacturers to provide rebates for Medicare Part B and Part D medicines.
- The IRA replaces the Part D CGDP with a new manufacturer discount program in 2025.
- Generic challenges to Eliquis patents may impact revenue due to pending legal proceedings.
- The Biden Administration proposed that drug prices could affect government licensing decisions.
- The implementation of Pillar Two is expected to increase the effective tax rate by approximately 1% in 2024.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=14272&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.